title: EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence; D005060:Europe; D006801:Humans; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy*; D010069:Oxadiazoles / Q000627:therapeutic use*
chemical_list: D010069:Oxadiazoles; C515878:ataluren
references.citation: Nat Biotechnol. 2013 Sep;31(9):771-3
references.pmid: 24022133
references.citation: Lancet Respir Med. 2014 Jul;2(7):539-47
references.pmid: 24836205